Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

China’s BeiGene gets U.S. approval for drug to treat rare form of lymphoma

The FDA approved BeiGene Ltd.’s lymphoma treatment Brukinsa, validating the China-based drugmaker’s strategy of largely using data from clinical trials held outside the U.S. to file for approval.

Read More »

Japanese drugmaker Takeda cuts full-year loss forecast

Takeda Pharmaceutical Co. trimmed the company’s full-year fiscal 2019 loss forecast on strong sales of core drugs and progress in consolidating with Shire Plc.

Read More »

Alexion’s Ultomiris wins FDA clearance for aHUS

The U.S. Food and Drug Administration approved Alexion Pharmaceuticals Inc.’s Ultomiris for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy for adult and pediatric patients.

Read More »

Alexion fortifies rare blood disorder drugs business

Alexion Pharmaceuticals Inc. agreed to buy smaller biotech company Achillion Pharmaceuticals Inc. in a deal initially valued at $930 million.

Read More »

Belgium’s UCB to buy Ra Pharmaceuticals

UCB will acquire U.S.-based Ra Pharmaceuticals in a $2.1 billion deal that will enable the Belgian drugmaker to offer new treatment options for several rare diseases in neurology and immunology.

Read More »

FDA Boosts Rare Disease Research with $15 Million in Grants

The U.S. Food and Drug Administration awarded $15 million in grants to fund 12 new clinical trials over the next four years to foster the development of rare disease treatments.

Read More »

FDA Approves Genentech’s Rituxan (rituximab) in Children With Two Rare Blood Vessel Disorders

The U.S. Food and Drug Administration approved Roche/Genentech’s Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in pediatric patients 2 years of age and older.

Read More »

Evotec and Takeda enter collaboration agreement

Evotec SE announced a strategic multi-year collaboration with Takeda Pharmaceutical Company Limited to establish at least five drug discovery programs across multiple therapeutic areas.

Read More »

Sumitomo Dainippon Pharma and Roivant Sciences Create Broad Strategic Alliance for New Medicines

The Sumitomo Dainippon-Roivant Alliance encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and Digital Innovation.

Read More »

Zogenix Buys Modis in $400 Million-Plus Deal

Zogenix, with headquarters in Emeryville, California, announced the acquisition of Oakland, California-based Modis. Both companies focus on rare diseases.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom